Needham & Company LLC reaffirmed their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a research note released on Monday morning, AnalystRatings.com reports. Needham & Company LLC currently has a $84.00 price target on the stock.
Several other equities research analysts have also recently weighed in on CRSP. Zacks Investment Research cut Crispr Therapeutics from a hold rating to a sell rating in a research note on Monday, September 30th. BidaskClub lowered Crispr Therapeutics from a strong-buy rating to a buy rating in a research report on Friday, December 13th. William Blair upgraded Crispr Therapeutics from a market perform rating to an outperform rating in a research report on Tuesday, November 19th. Canaccord Genuity lifted their price objective on Crispr Therapeutics from $72.00 to $80.00 and gave the stock a positive rating in a research note on Wednesday, November 20th. Finally, Piper Jaffray Companies reiterated a buy rating and issued a $104.00 target price on shares of Crispr Therapeutics in a report on Monday, December 16th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have given a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $71.38.
NASDAQ CRSP opened at $67.23 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. The firm has a market cap of $3.71 billion, a PE ratio of -19.54 and a beta of 3.31. The stock’s 50 day simple moving average is $63.87 and its 200 day simple moving average is $50.25. Crispr Therapeutics has a one year low of $24.56 and a one year high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The business had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. As a group, equities analysts expect that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In related news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total transaction of $412,500.00. Following the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at $412,500. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 56,118 shares of company stock valued at $3,620,760. Insiders own 21.40% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the company. Nikko Asset Management Americas Inc. raised its stake in Crispr Therapeutics by 48.4% during the 3rd quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after buying an additional 906,006 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Crispr Therapeutics by 19.6% during the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after purchasing an additional 121,176 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of Crispr Therapeutics by 23.9% in the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after purchasing an additional 116,540 shares in the last quarter. Orbimed Advisors LLC bought a new position in shares of Crispr Therapeutics in the 3rd quarter worth $21,167,000. Finally, Morgan Stanley grew its position in Crispr Therapeutics by 6.1% in the 2nd quarter. Morgan Stanley now owns 284,984 shares of the company’s stock valued at $13,423,000 after purchasing an additional 16,361 shares during the period. Institutional investors own 49.82% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: What is meant by buying and selling pressure?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.